Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ORMP
ORAMED PHARMACEUTICALS INC.
NASDAQ
$5.03
▼ DOWN 1.37% (-0.07)

KEY STATISTICS

Market Cap$205.86 M
52w High$5.47
52w Low$2.09
Dividend Yield6.79%
FrequencySpecial
P/E2.61
Volume154.13K
Shares Out.40.93M

COMPANY

LEADERSHIP

Nadav Kidron
CHIEF EXECUTIVE
Nadav Kidron

COMPENSATION 2026

Salary$619,529
Stock Awards$3,709,269
Incentive Plan Pay$0
All Other Comp.$65,927
Total$4,774,460

ABOUT

SECTOR
Healthcare
WENT PUBLIC
May 1, 2007
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
13

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

SPLIT RECORD

DATETYPERATIO
2013-01-23Reverse1:12
2004-06-14Forward33:10

PRICE

$5.03 ▼ DOWN 1.37% (−$0.07)
OVERLAYS
$5.04$5.08$5.129:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.03

About Oramed Pharmaceuticals Inc.

https://www.oramed.com ↗

Oramed Pharmaceuticals develops oral peptide-based treatments for diabetes, including insulin and GLP-1 capsules, with products in Phase I and II trials, aiming to revolutionize drug delivery.

INDUSTRY

Biotechnology

A PRODUCT ORAMED PHARMACEUTICALS INC. IS KNOWN FOR

ORMD-0801
ORMD-0801

ORMD-0801 is an oral insulin capsule for type 2 diabetes and NASH, with plans to restart Phase 3 trials targeting responsive patients after a 2023 setback, representing Oramed's main candidate for future commercialization.

COMPETITORS

COMPETITOR
LLY COMPARE
MNKD COMPARE
NVO COMPARE
RANI COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
41
LISTED HERE
10
RANKED BY POSITION SIZE
IWM
0.00% · 626.3K
VTWO
0.00% · 190.6K
SILX
0.32% · 98.6K
GSSC
0.03% · 58.0K
AVSC
0.01% · 55.6K
DFAS
0.00% · 40.5K
XRSG.L
0.01% · 31.1K
RSSL
0.01% · 16.1K
OMFS
0.01% · 7.0K
URTY
0.00% · 1.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
24.41%
HOLDERS
88
TOP 12 OF 88 · RANKED BY POSITION SIZE
Bml Capital Management, LLC
3.2M sh · $10.77M
Mercer Global Advisors Inc /Adv
1.9M sh · $6.5M
Murchinson Ltd.
1.8M sh · $4.62M
Boothbay Fund Management, LLC
845.4K sh · $2.23M
Marxe Austin W & Greenhouse David M
790.0K sh · $6.37M
Morgan Jess S & Co Inc
366.4K sh · $2.37M
Marshall Wace, Llp
259.6K sh · $882.68K
Rathbones Group Plc
233.0K sh · $792.26K
Citadel Advisors LLC
196.0K sh · $558.66K
Dimensional Fund Advisors LP
158.2K sh · $537.74K
Wells Fargo & Company/Mn
157.6K sh · $535.79K
Ritholtz Wealth Management
155.5K sh · $528.63K

RATINGS SNAPSHOT

Overall rating: A+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets5
Debt To Equity4
Price To Earnings3
Price To Book4
Overall Score4

TRADES BY CONGRESS

HOUSE TRADES
Brad Knott
Brad Knott
Sale
2025-01-10
 Andrew Garbarino
Andrew Garbarino
Sale (Full)
2022-01-14

INSIDER TRADES

★
OFFICER: COO & CBO
Hexter Joshua
Sale · 137.0K shares
2026-07-01
★
OFFICER: COO & CBO
Hexter Joshua
Sale · 50.0K shares
2026-07-02
★
OFFICER: CHIEF FINANCIAL OFFICER
Gabay Avraham
Sale · 73.4K shares
2026-07-01
★
OFFICER: COO & CBO
Hexter Joshua
Purchase · 50.0K shares
2026-07-02

SECTORS PEERS

PEERPRICE
STTK$7.04COMPARE
OVID$2.80COMPARE
IFRX$2.23COMPARE
MGNX$4.13COMPARE
CNTB$2.23COMPARE
COYA$4.59COMPARE
KLRS$4.03COMPARE
IMA$5.34COMPARE